binarypublishSwiss tech startup Aesyra recently secured $3 million in a seed funding round for the development and commercialization of its AesyBite sleep disorder treatment device. The round was led by Supermoon Capital, a venture firm that solely focuses on the sleep tech market. Other participants included Creadd Ventures and the Zürcher Kantonalbank.
- The AesyBite device assists in treating sleep bruxism, a disorder causing the sufferer to clench and grind their teeth during sleep, resulting in teeth damage, sleep issues, headaches, and facial pain.
- The device utilizes artificial intelligence to monitor occlusal or dental activity, providing a bio-feedback signal in the form of a mild vibration to halt bruxism without disturbing the user’s sleep.
- Aesyra claims the device can reduce the occurrence of bruxism by over 70%.
- Supermoon Capital’s Managing Partner, Michael Masterson, and Creadd’s Founder Lorenzo Leoni, will be joining Aesyra’s board of directors.
Aesyra’s technology, including the AesyBite device, was developed in collaboration with the Federal Institute of Technology of Lausanne (EPFL), leveraging 10 years of sleep research data from the institute. Aesyra was established in 2018 and subsequently awarded monetary prizes at a major European startup conference, the START Summit.
Aside from treating sleep bruxism, Aesyra states that the AesyBite device is also effective for sleep apnea treatment, citing a connection between the two disorders. Supermoon Capital, the round leader, has a history of investing in various sleep tech companies globally. Such an investment further enables the firm to consolidate its position as a pre-eminent source of expertise and capital within the fast-growing ‘Night Market,’ catered to the 75% of Americans dealing with recurring sleep problems.
